Altimmune's (ALT) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Altimmune (NASDAQ:ALT - Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $12.00 price target on the stock.

ALT has been the subject of several other reports. JMP Securities cut their target price on shares of Altimmune from $25.00 to $24.00 and set a market outperform rating for the company in a research note on Friday. B. Riley reissued a buy rating and issued a $20.00 price objective on shares of Altimmune in a research report on Thursday, March 28th. The Goldman Sachs Group began coverage on shares of Altimmune in a research note on Wednesday, January 24th. They issued a neutral rating and a $13.00 price target on the stock. Finally, Guggenheim downgraded shares of Altimmune from a buy rating to a neutral rating in a research report on Monday, April 29th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Altimmune currently has a consensus rating of Moderate Buy and a consensus price target of $17.25.

Altimmune Stock Up 6.1 %

Shares of NASDAQ:ALT traded up $0.45 during midday trading on Tuesday, reaching $7.82. 3,356,710 shares of the company were exchanged, compared to its average volume of 5,037,537. The firm has a market cap of $554.44 million, a PE ratio of -4.92 and a beta of 0.22. Altimmune has a fifty-two week low of $2.09 and a fifty-two week high of $14.84. The stock has a fifty day simple moving average of $8.45 and a two-hundred day simple moving average of $7.99.

Altimmune (NASDAQ:ALT - Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. Altimmune had a negative return on equity of 46.96% and a negative net margin of 22,645.37%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the firm posted ($0.40) EPS. As a group, analysts forecast that Altimmune will post -1.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ALT. Timelo Investment Management Inc. increased its stake in shares of Altimmune by 2,597.0% in the 4th quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company's stock valued at $9,102,000 after acquiring an additional 779,095 shares in the last quarter. Lighthouse Investment Partners LLC bought a new stake in Altimmune in the fourth quarter valued at $4,493,000. GSA Capital Partners LLP raised its holdings in shares of Altimmune by 153.1% during the third quarter. GSA Capital Partners LLP now owns 445,868 shares of the company's stock valued at $1,159,000 after purchasing an additional 269,676 shares during the period. Gerber LLC bought a new position in shares of Altimmune during the 4th quarter worth about $2,878,000. Finally, Sectoral Asset Management Inc. acquired a new stake in shares of Altimmune in the 4th quarter valued at about $1,922,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.